肠道菌群在银屑病治疗中的研究进展  

Research progress of gut microbiome in the treatment of psoriasis

作　　者：文渚媛 王萍[1] 陈爱军[1] WEN Zhuyuan;WANG Ping;CHEN Aijun(Department of Dermatology,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院皮肤科,重庆400016

出　　处：《重庆医学》2024年第1期1-4,10,共5页Chongqing medicine

摘　　要：银屑病为免疫介导的慢性、复发性、系统性炎症性皮肤病。肠道菌群及其代谢产物与宿主之间的平衡和交流对维持机体正常功能如免疫稳态、维生素合成等发挥重要作用。近年来研究发现,与健康人群相比,银屑病患者肠道菌群的微生物丰度及多样性发生明显变化,包括肠道微生物群失调和短链脂肪酸(SCFAs)产生减少、Firmicutes/Bacteroidetes(F/B)异常等。而银屑病患者在进行系统药物治疗、生物制剂治疗和小分子化学药治疗后肠道菌群也发生了变化,提示肠道微生物群可能为评估治疗效果的潜在生物标志物。银屑病和肠道微生物群之间的作用关系尚不完全明了,仍需进一步研究。Psoriasis is a chronic,recurrent,systemic inflammatory skin disease that is immune-mediated.The balance and communication between the intestinal microbiota and its metabolites and the host play an important role in maintaining the body’s normal functions,such as immune homeostasis and vitamin synthesis.Recent studies have found that compared with the healthy individuals,the psoriasis patients have experienced significant changes in the abundance and diversity of intestinal microbiota,including an imbalance in intestinal microbiota,reduced production of short-chain fatty acids(SCFAs),and abnormal Firmicutes/Bacteroidetes(F/B)ratio.The gut microbiota also changed after systematic medication treatment,biologic agents treatment and small molecule chemotherapy,indicating that the gut microbiota could be a potential biomarker for assessing treatment efficacy.The relationship between psoriasis and gut microbiota is not fully understood,and further research is needed.

关 键 词：银屑病 肠道菌群 益生菌 生物制剂 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]